Practical articles organized by catalog use, documentation review, custom planning, and research procurement.
Choose a category to narrow the published guidance.
14 articles
TB-500 and thymosin beta-4 are often conflated, but they differ completely in chemical structure, molecular weight, and research evidence. This article explains the fundamental difference and why it matters.
Read guidance →
On 30 July 2026, a federal judge sentenced the owner of Paradigm Peptides to 70 months in prison. This article explains what the court record established, what it never showed, and why the research-use-only label protected nobody.
Read guidance →
CJC-1295 + Ipamorelin is one of the most-searched peptide stacks in the U.S. This article explains each peptide’s mechanism, how they raise growth hormone through different receptors, and why the combination has never been tested in humans.
Read guidance →
GLOW is not a single peptide but a blend of GHK-Cu, BPC-157, and TB-500. This article explains its composition ratios, common specifications, and why the blend itself has no evidence.
Read guidance →
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk under the code AM833. It acts through amylin and calcitonin receptors, a different pathway from GLP-1 drugs. This article covers how it works, published Phase III data, the gap between trial dosing and community dosing, and its legal status as of September 2026.
Read guidance →
Retatrutide is the most-searched investigational peptide, activating GIP, GLP-1, and glucagon receptors simultaneously. This article explains its molecular design, mechanism, and how it differs from semaglutide and tirzepatide.
Read guidance →
The six most-discussed therapeutic peptides in 2026 differ in mechanism, evidence strength, and regulatory status. This article uses a comparison table to show where each one actually stands.
Read guidance →
Many of BPC-157's systemic effects originate from gastrointestinal experiments. This article explains its current research status in gut integrity, inflammatory signaling, and gastrointestinal repair from the perspective of the gut-brain axis — and why human evidence remains limited.
Read guidance →
Peptides are short chains of amino acids that act as precise signals in the body. This article explains the basics of peptides from five perspectives — definition, structure, peptide bond properties, chain-length classification, and post-translational modification — to help you understand their roles in metabolism, growth, and cell communication.
Read guidance →
Retatrutide (LY3437943) is the world's first GIP/GLP-1/glucagon triple receptor agonist to enter Phase III clinical trials. Phase II data have shown a weight reduction of up to 24.2% at 48 weeks, bringing transformative hope for the treatment of obesity and type 2 diabetes.
Read guidance →
A practical checklist for identifying a catalog record and giving the review team enough information to answer accurately.
Read guidance →
Understand the difference between a catalog statement, a mapped historical file, and documentation for the material currently being quoted.
Read guidance →
The sequence, modification, purity, quantity, analytical, destination, and timing details that make a custom request reviewable.
Read guidance →
A controlled way to compare identity, specification, evidence, destination requirements, and lead time before a purchase decision.
Read guidance →